Drug

Tinengotinib clinical trials

Also written TT-00420.

studies test it: 9
open now: 4
in phase 3: 2
first study started: 2019

Keep track of what changes. Save the tinengotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

9 studies that test it; most in 2026 (3)

Studies that test tinengotinib, by start year
Year	Studies
2019	1
2020	1
2021	1
2023	2
2024	1
2026	3

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 5
Phase 3: 2

What it is tested for

Each study’s main condition, where its own words name it.

Cholangiocarcinoma: 3
Triple Negative Breast Neoplasms: 1
Carcinoma, Renal Cell: 1
Prostatic Neoplasms: 1
Breast Neoplasms: 1

Who runs them

Industry 8 · Other 1

TransThera Sciences (Nanjing), Inc. (8) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)

Often tested with

Tested in the same studies.

Toripalimab (1)

Studies

Open first, then newest update. How each study uses tinengotinib is read from its arms, and is right about nine times in ten.

Testing it · 9

Given in every arm · 4 — tinengotinib is usual care beside what is tested

Codes

What other systems call tinengotinib · ClinicalTrials.gg INT018403

UNII (FDA) WZ9TJ0L9Y8TINENGOTINIBOne source FDA
NCI Thesaurus C162532TinengotinibOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	WZ9TJ0L9Y8	TINENGOTINIB	One source FDA
NCI Thesaurus	C162532	Tinengotinib	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.